BeneluxBio consists of a team of four people, each with their own complementary areas of expertise, as well as a number of consultants. In addition, BeneluxBio is part of a network that emerged following Merck’s (MSD) acquisition of Schering-Plough—and, by extension, Organon—and the subsequent dissolution of Organon’s R&D department, which resulted in specialists being dispersed in all directions.

With a commitment to innovation and patient care, we aim to develop new medicines that address infectious diseases,epilepsy in cooperation with the University of Maastricht, and multiple myeloma ( via molecular glues).Many compounds  were designed and developed under a program of the NCI.Director is mr. J.H.A. Cornelesen
We are gratefull to our former director mr. R.G. Dassen(Itteren,Netherlands)for his relentless commitment to the Stichting Eigen Regie